Research and Markets has announced the addition of the "Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) - Pipeline Insights, 2017" report to their offering.
Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Norepinephrine-Dopamine Reuptake Inhibitors (NDRI).
The This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.
This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Norepinephrine-Dopamine Reuptake Inhibitors (NDRI).
This report also assesses the Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.
Key Topics Covered:
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Overview
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Disease Associated
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Pipeline Therapeutics
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Therapeutics under Development by Companies
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Filed and Phase III Products
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Phase II Products
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Phase I and IND Filed Products
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) Discovery and Pre-Clinical Stage Products
- Drug Candidate Profiles
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) - Therapeutics Assessment
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) - Discontinued Products
- Norepinephrine-Dopamine Reuptake Inhibitors (NDRI) - Dormant Products
- Companies Involved in Therapeutics Development for Norepinephrine-Dopamine Reuptake Inhibitors (NDRI)
- Appendix
For more information about this report visit http://www.researchandmarkets.com/research/3xjz3x/norepinephrinedop
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123005669/en/